Receipt date: 04/27/2009

Approved for use through 03/31/2007, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction 1995, no describe sons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted:  $\frac{4/27/20}{09}$ 

(use as many sheets as necessary) Sheet of

Complete if Known					
Application Number	09/756,125				
Filing Date	1/9/2001				
First Named Inventor	Tadamitsu KISHIMOTO				
Art Unit	1644				
Examiner Name	Gerald R. EWOLDT				
Attorney Docket Number	053466-0296				

U.S. PATENT DOCUMENTS					
Examin er Cite No.1	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
		Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
	C1	2002/0187150 A1	12/12/2002	Mihara et al.	
	C2	2003/0236260 A1	12/25/2003	Shimojo et al.	
	C3	2004/0115197 A1	06/17/2004	Yoshizaki et al.	
	C4	2006/0292147 A1	12/28/2006	Yoshizaki et al.	
	C5	5,670,373 A	09/23/1997	Kishimoto	
	C6	6,723,319 B1	04/20/2004	Ito et al.	

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite Foreign Patent Document No.1 Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	
	C7	CA 2,031,455 A1	06/05/1992	Biotest Pharma GmbH et al.			
	C8	JP 04-187645 A	07/06/1992	Kishimoto et al.		Α	
	C9	EP 0 381 168 A	08/08/1990	Mochida Pharmaceutical Co., Ltd.			
	C10	EP 0 628 639	12/14/1994	Chugai Seiyaku Kabushiki Kaisha			
	C11	EP 0 791 359 A1	08/27/1997	Chugai Seiyaku Kabushiki Kaisha			
	C12	WO 2004/096273 A1	11/11/2004	Chugai Seiyaku Kabushiki Kaisha			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*  Cite No.1  Cite No.1  Cite No.1  Cite No.1  Cite No.1  Cite No.1  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (whe			
000000000000000000000000000000000000000	<del>64</del> 3	Office Action in corresponding Chilcan Application 1237-2004, 7 pages.	2000000000
	C14	Office Action in corresponding Chilean Application 1243 2004, 7 pages	
	045	TUDANO ( I MB) I	
	C15	HIRANO et al., "Biological and clinical aspects of interleukin 6," Immunology Today, 1990, 11(12):443-	
	C16	SIPE et al., "Cytokine reduction in the treatment of joint conditions," Mediators of Inflammation, 1994, 3:243-256.	
		Initials* No.1	Examiner Initials*  Cite No.1  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.  C13  Office Action in corresponding Chilean Application 1237-2004, 7 pages.  C14  Office Action in corresponding Chilean Application 1243-2004, 7 pages.  C15  HIRANO et al., "Biological and clinical aspects of interleukin 6," Immunology Today, 1990, 11(12):443-449.  C16  SIPE et al., "Cytokine reduction in the treatment of joint conditions," Mediators of Inflammation, 1994,

Lined through docs in improper format and not in English.

Examiner Signature	/Gerald Ewoldt/	Date Considered	08/08/2009
	Water and the second se		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Receipt date: 04/27/2009 09756125 - GAU: 1644 Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. (MODIFIED) PATENT AND TRADEMARK OFFICE 09758125 053466/0296 APPLICANT INFORMATION DISCLOSURE CITATION Tadamitsu KISHIMOTO, et al. **FILING DATE** GROUP ART UNE (Use several sheets if necessary) January 9, 2001 U.S. PATENT DOCUMENTS **EXAMINER** DOCUMENT FILING DATE SUB-REF DATE NAME CLASS INITIAL IF NUMBER CLASS APPROPRIATI 5,591,827 1/7/97 A1 Brakenhoff et al. 530 351 5,559,012 9/24/96 A2 Brailly et al. 435 70.21 5,210,075 5/1993 Scholz et al. 514 **A3** 14 5,888,510 03/1999 Kishimoto et al. A4 141.1 FOREIGN PATENT DOCUMENTS DOCUMENT TRANSLATIO SUB-DATE COUNTRY REF CLASS NUMBER **CLASS** YES 3-291236 04/1990 **A5** Japan 4-89433 07/1990 Japan A6 0 617 126 09/1994 Europe **A7 A8** 0 399 429 11/1990 Europe 2 694 767 02/1994 France Α9 92/19759 A10 11/1992 WIPO 39 39 706 03/1991 Federal Republic of Germany A11 0 572 118 12/1993 A12 Europe 0 409 607 A13 01/1991 Europe 91/07986 06/1991 WIPO A14 AOTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

R	A15	Harigai et al., "Rheumatoid Adherent Synovial Cells Produced B Cell Differentiation Factor Activity Neutralizable			
		By Antibody to B Cell Stimulatory Factor-2/Interleukin 6, The Journal of Rhematology, pp. 1616-1622, (1988)			
1	414	Yasukawa et al., "A Research on Inhibitor of Interleukin-6", Journal of TOSOH Research, Vol. 35(2): pp. 77-91,			
	A16	(1991)			
		latsuda et la., "Establishment of An Interleukin 6 (1L-6)/B Cell Stimulatory Factor 2-dependent Cell Line And			
	A17	Preparation of Anti-Il 6 Monoclonal Antibodies", Eur. J. Immunol., Vol. 18, pp. 951-956, (1988)			
		VCH Verlagsgesellschaft mbH, D-6940 Weinheim, 1988			
	410	Hirata et al., "Characterization of IL-6 Receptor Expression by Monoclonal and Polycholan Antibodies", The Journ			
	A18	of Immunology, Vol. 143, pp. 2900-2906, (1989)			
	410	Hirano et al., "Excessive Production of Interleukin 6/B Cell Stimulatory Factor-2 in rheumatoid Arthritis",			
	A19	Eur. J. Immunol. 18. pp. 1797-1801, (1988), VCH Verlagsgesellschaft mbH, D-6940 Weinheim, 1988			

EXAMINER ). While

DATE CONSIDERED

EXAMINER: Initial is citation considered, whether or not citation is in conformance with MPEP 609; Draw line throughtain if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-14	40	II S DEDARTME	NT OF COMMERCE	ATTY DOCKET NO		CEDIAL NO	Page 2	of 4	
Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. SERIAL NO. 053466/0296 09/756125							
		053466/0296 09/756/25				5			
INFO	RMAT	ON DISCLOSURE	CITATION		damitsu KISHI	MOTO, et al.			
				FILING DATE		GROUP AR	T UNIT		
	(Use several sheets if necessary)				2001	164	14		
			U.S. PATEN	T DOCUMENTS		1	<u>, ,                                   </u>		
EXAMINER		DOCUMENT				SUB-	FILING	G DATI	
INITIAL	REF	NUMBER	DATE	NAME	CLASS	CLASS	1	IF	
							APPRO	PRIAT	
	<u></u>		FOREIGN PAT	TENT DOCUMENTS					
	Γ	DOCUMENT			T	SUB-	TRANS	LATIO	
	REF	NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	NO	
		OTHER DOCU	JMENTS (Including	Author, Title, Date, Pe	ertinent Pages,	Etc.)	<b>-</b>	<del></del>	
a/		Yasukawa et al., "A	Research on Inhibitor	of Interleukin-6", Journa	l of TOSOH Res	earch, Vol. 35	i(2): pp. 7	7-91,	
IV	A20	(1991)							
	_	Matsuda et la., Est	ablishment of As Inter	culin 6 (IL-6)/B Coll Sti	mulatory Factor	2 dependent (	Cell Line	-md	
	A21	Preparation of Anti-	ii 6 Monecional Anus	A TEL Ammond	Vol. 18, pp. 95	1-056, (1988)	<del></del> -		
0/		Houssiau, et al., "Ir	nterleukin-6 in Synolvia	l Fluid and Serum of Pat	ients with Rheur	natoid Arthriti			
17	A22	Inflammatory Arthritis", Arthritis and Rheumatism 31, pp. 784-788, (1988)							
		Waage et al., Interle	zukin-6 Synovial Fluid	from Patients with Arthri	itis", Clinical In	vnunology and	Immunop	atholog	
	A23	50, pp. 394-398, (19	989), 1 <b>989</b> Academic I	ress, Inc.					
		Bhardwaj et al., "IL-6/IFN-β2 In Synovial Effusions of Patient s with Rheumatoid Arthritis and Other Arthritide							
\ \ \	A24	J. of Immunology 143, pp. 2153-2159, (1989), 1989 The American Association of Immunologists							
		Aderka et al, "II-6 I	nhibits Lipopolysaccha	ride-induced Tumor Neci	rosis Factor Pro-	duction in Cult	ured Hum	an	
	A25	Monocytes U937 Co	ells, and In Mice", <u>J of</u>	Immunology 143, pp. 35	17-3523, (1989)	., 1989 The A	merican		
		Association of Immunologists							
		Schindler et al., "Co	orrelations and Interact	ions in the Production of	Interleukin-6 (II	L-6), IL-1, and	I Tumor N	ecrosis	
ļ	A26	Factor (TNF) in Hu	man Blood Mononucle	ar Cells: IL-6 suppresses	IL-I and TNF",	Blood 75, pp.	40-47, (1	990).	
		1990 The American	Society of Mehatolog	y					
		Saito et al., "Prepar	ation of Soluble Murin	e Il-6 Receptor and Anti-	Murine II-6 Rec	eptor Antibodi	es", <i>The J</i>	ournal	
	A27	of Immunology 147,	pp. 168-173, (1991),	1991 The American Asso	ciation of Imm	unologists			
	4.50	Yasukawa et al., "In	nhibitors of Interleukin	6", Toso Kenkyu Hokoku	<i>32(20)</i> , pp. 77-	91, ABSTRAC	T, (1991)	)	
\	A28						<del></del>	<del></del>	
EXAMINE	R	TA	0/10/1	DATE CONSIDE	RED /	, /			
	0	r. 1/2 /	Marky 4.		3/16	101			
* EXA	MINER	: Initial if citation	considered, wheth	er or not citation is i	n conformanc	e with MPE	P 609; D	raw li	
to a	ugn cita mlicant	non il liot ili colito	mance and not con	sidered. Include any	copy of this fo	orm with nex	a commi	ınıcati	



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO. (MODIFIED) 09 PATENT AND TRADEMARK OFFICE 053466/0296 756125 APPLICANT Tadamitsu KISHIMOTO, et al. INFORMATION DISCLOSURE CITATION FILING DATE **GROUP ART UNIT** 1644 January 9, 2001 (Use several sheets if necessary) U.S. PATENT DOCUMENTS EXAMINER DOCUMENT SUB-FILING DATE
IF APPROPRIAT DATE NAME CLASS REF INTITAL. CLASS NUMBER FOREIGN PATENT DOCUMENTS TRANSLATIO DOCUMENT SUB-REF DATE COUNTRY CLASS NUMBER CLASS YES OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Mihara et al., "Interleukin 6 Inhibits Delayed-Type Hypersensitivity and the Development of Adjuvant Arthritis", A29 Eur. J. Immunol. 21, pp. 2327-2331, (1991) Heremans et al., "Protective Effect Of Anti-Interleukin-6 Antibody Against Endotoxin, Associated with Paradoxica Increased IL-6 Levels", Eur. J. Immunol. 22, pp. 2395-2401, (1992), VCH Verlagsgesellschaft mbH, D-6940 A30 Weinheim, 1992 Wendling et al., "Treatment of Severe Rheumatoid Arthritis by Anti-Interleukin 6 Monoclonal Antibody", J. of A31 Rheumatology 20, pp. 259-262, (1993) Sack et al., "Interleukin-6 In Synovial Fluid is Closely Associated with Chronic Synovitis in Rheumatoid Arthritis" A32 Rheumatol. Int. 13, pp. 45-51, (1993) Madhok et al., "Serum Interleukin-6 Levels in Rheumatoid Arthritis: Correlations with Clinical and Laboratory A33 Indices of Disease Activity", Annals of the Rheumatic Diseases 52, pp. 232-234, (1993) Tilg et al., Interleukin-6 (IL-6) as an Anti-inflammatory Cytokine: Induction of Circulating IL-1 Receptor Antagon and Soluble Tumor Necrosis Factor Receptor p55", Blood 83, pp. 113-118, (1994), 1994 The American Society of A34 Hematology Punzi et al., "Interrelationship Between Synovial Fluid Interleukin (IL)-6, Il-1β and Disease Activity Indices in A35 Rheumatoid Arthritis", Rheumatol. Int. 14, pp. 83-84, (1994), Springer-Verlag 1994 Monier et al., "Growth Factor Activity of Il-6 in the Synovial flud of Patients with Rheumatoid Arthritis", Clinical A36 and Experimental Rheumatology 12, pp. 595-602, (1994) Fukamachi et al., "Interleukin-6 Receptor (11-6R) Dynamics in Patients with Rheumatoid Arthritis", Japanese A37 Journal of Inflamation 14, pp. 489-497, (1994) **EXAMINER** DATE CONSIDERED mitial if citation considered, whether or not citation is in conformance with MPEP 609; Draw I

through citation if not in conformance and not considered. Include any copy of this form with next communicati to applicant.

Receipt date: 04/27/2009

to applicant.



09756125 - GAU: 1644

U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO. Form PTO-1449 09 756125 (MODIFIED) PATENT AND TRADEMARK OFFICE 053466/0296 APPLICANT INFORMATION DISCLOSURE CITATION Tadamitsu KISHIMOTO, et al. GROUP ART UNIT FILING DATE (Use several sheets if necessary) January 9, 2001 1644 U.S. PATENT DOCUMENTS FILING DATE DOCUMENT **EXAMINER** SUB-CLASS DATE NAME REF 1F **CLASS** INITIAL NUMBER APPROPRIATI FOREIGN PATENT DOCUMENTS TRANSLATIO SUB-DOCUMENT **CLASS** DATE COUNTRY REF NUMBER CLASS YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Tanabe, M. et al., "Remarkable Elevation of Interleukin 6 and Interleukin 8 Levels in the Bone Morrow Serum of A38 Patients with Rheumatoid Arthritis", The Journal of Rheumatology 21, pp. 830-835, (1994) Mihara et al., "Interleukin-6 (IL-6) Induces the Proliferation of Synovial Fibroblastic Cells in the Presence of Solubl A39 1L-6 Receptor", British Journal of Rheumatology 34, pp. 321-325, (1995) Cicuttini et al., "Serum IL-4, IL-10 and IL-6 Levels in Inflammatory Arthritis", Rheumatol. Int. 14, pp. 201-206, A40 (1995), Springer-Verlag 1995 Scholz et al., "Interleukin 6 in diseases: Cause or Cure?", Immunopharmacology 31, pp. 131-150, (1996), A41 1996 Elsevier Science B.V. Santo et al., "Differential Effects of 1L-6 on Systemic and Central Production of TNF: A Study with 1L-6-Deficient A42 Mice", Cytokine 9, pp. 300-306, (1997), 1997 Academic Press Limited Suzuki et al., "Anti-human Interleukin-6 Receptor Antibody Inhibits Myeloma Growth in vivo", Eur. J. Immunol. A43 22, pp. 1989-1993, (1992), VCH Verlagsgesellschaft mbH, D-6940 Weinheim 19921 Suzuki et al., "Anti-Murine 1L-6 Receptor Antibody Inhibits 1L-6 Effects in Vivo", Immunology Letters 30, A44 pp. 17-21, (1991), 1991 Elsevier Science Publishers B.V. Sato et al., "Reshaping a Human Antibody to Inhibit the Interleukin 6-dependent Tumor Cell Growth", Cancer A45 Research 53, pp. 851-856, (1993) Wijdenes et al., "Interleukin-6 Antobodies in Rheumatoid Arthritis", Journal of Interferon Research 14, A46 pp. 297-298, (1994) Herve, P. et al., Immunological Reviews 129, pp. 31-55, (1992) A47 DATE CONSIDERED **EXAMINER** Initial If chation considered, whether or not citation is in conformance with MPEP 609; Draw li through citation if not in conformance and not considered. Include any copy of this form with next communicati